Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Arbutus believes the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Arbutus' pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has achieved meaningful functional cure rates in patients with cHBV when administered as combination therapy. Plans are underway to advance imdusiran into a Phase 2b clinical trial. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit .WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET.
華明斯特，賓夕法尼亞州，2024年11月26日（全球新聞通訊） -- 阿爾布圖斯生物製藥公司（納斯達克：ABUS）(「阿爾布圖斯」或「公司」)是一家臨床階段的生物製藥公司，利用其廣泛的病毒學專業知識，開發針對慢性乙型肝炎病毒（cHBV）感染的功能性治癒方案。今天公司宣佈，將參加2024年12月3日東部時間上午11:00舉行的虛擬H.C. Wainwright @ Home爐邊聊天系列。
To access the live webcast of the fireside chat, please visit: . An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
要訪問爐邊聊天的現場直播網絡廣播，請訪問：。活動結束後，阿爾布圖斯網站將提供網絡廣播的歸檔回放，限時可用。
About Arbutus
關於越桔公司
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Arbutus believes the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Arbutus' pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has achieved meaningful functional cure rates in patients with cHBV when administered as combination therapy. Plans are underway to advance imdusiran into a Phase 2b clinical trial. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit .
阿爾布圖斯生物製藥公司（納斯達克：ABUS）是一家臨床階段的生物製藥公司，利用其廣泛的病毒學專業知識開發具有不同作用機制的新型治療藥物，這些藥物可能結合起來，爲慢性乙型肝炎病毒（cHBV）患者提供功能性治癒。阿爾布圖斯認爲，開發功能性治癒的成功關鍵在於抑制HBV DNA、減少表面抗原以及增強HBV特異性免疫反應。阿爾布圖斯內部開發的專有化合物管線包括RNA干擾治療藥物imdusiran（Ab-729）和口服PD-L1抑制劑Ab-101。在聯合療法下，Imdusiran在cHBV患者中已實現有意義的功能性治癒率。目前計劃將Imdusiran推進至20億臨床試驗。Ab-101目前正在進行1a/10億臨床試驗的評估。欲了解更多信息，請訪問。
Contact Information
聯繫信息
Investors and Media
投資者和媒體
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
Lisa M. Caperelli
投資者關係副總裁
電話：215-206-1822
電子郵件：lcaperelli@arbutusbio.com